Katherine C. Verbist

Katherine C. Verbist

Auto-generated profile, based on publicly available information

Katherine C. Verbist

Department of Oncology and

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Cell
Verified
Journal Article
Closed access
CDChristopher P. Dillon
Christopher P. Dillon
RWRicardo Weinlich
Ricardo Weinlich
DRDiego A. Rodriguez
Diego A. Rodriguez
JCJames G. Cripps
James G. Cripps
GQGiovanni Quarato
Giovanni Quarato
DGDouglas R. Green
Douglas R. Green

1 July 2016 in Cell Host & Microbe
Verified
Journal Article
Closed access
SNShoko Nogusa
Shoko Nogusa
RTRoshan J. Thapa
Roshan J. Thapa
CDChristopher P. Dillon
Christopher P. Dillon
SLSwantje Liedmann
Swantje Liedmann
TOThomas H. Oguin
Thomas H. Oguin
SBSiddharth Balachandran
Siddharth Balachandran

11 April 2016 in Nature
Verified
Journal Article
Open access
PDF file
KVKatherine C. Verbist
Katherine C. Verbist
CGCliff S. Guy
Cliff S. Guy
SMSandra Milasta
Sandra Milasta
SLSwantje Liedmann
Swantje Liedmann
MKMarcin Kaminski
Marcin Kaminski
DGDouglas R. Green
Douglas R. Green
The asymmetric distribution of mTORC1 and c-Myc in the first division of daughter cells of activated CD8 T cells affects the proliferation, metabolism and differentiation potential of their progeny. Asymmetric cell division occurs widely during development and other biological processes. T lymphocytes, upon activation by antigen-presenting cells, can undergo asymmetric cell division and this study provides a metabolic explanation for how that asymmetry, once established, is maintained subsequently. Katherine Verbist et al. show that asymmetric assortment of amino acid transporters leads to asymmetric distribution of the signalling complex mTORC1 and transcription factor c-Myc in the first division daughters of activated CD8 T cells. mTORC1 and c-Myc activity correlate with the proliferative potential of the resulting progeny. Asymmetric cell division, the partitioning of cellular components in response to polarizing cues during mitosis, has roles in differentiation and development1. It is important for the self-renewal of fertilized zygotes in Caenorhabditis elegans and neuroblasts in Drosophila, and in the development of mammalian nervous and digestive systems1. T lymphocytes, upon activation by antigen-presenting cells (APCs), can undergo asymmetric cell division, wherein the daughter cell proximal to the APC is more likely to differentiate into an effector-like T cell and the distal daughter is more likely to differentiate into a memory-like T cell2. Upon activation and before cell division, expression of the transcription factor c-Myc drives metabolic reprogramming, necessary for the subsequent proliferative burst3. Here we find that during the first division of an activated T cell in mice, c-Myc can sort asymmetrically. Asymmetric distribution of amino acid transporters, amino acid content, and activity of mammalian target of rapamycin complex 1 (mTORC1) is correlated with c-Myc expression, and both amino acids and mTORC1 activity sustain the differences in c-Myc expression in one daughter cell compared to the other. Asymmetric c-Myc levels in daughter T cells affect proliferation, metabolism, and differentiation, and these effects are altered by experimental manipulation of mTORC1 activity or c-Myc expression. Therefore, metabolic signalling pathways cooperate with transcription programs to maintain differential cell fates following asymmetric T-cell division.

31 March 2016 in Blood
Verified
Journal Article
Open access
PDF file
RDRupali Das
Rupali Das
PGPeng Guan
Peng Guan
LSLeslee Sprague
Leslee Sprague
KVKatherine Verbist
Katherine Verbist
PTPaige Tedrick
Paige Tedrick
KNKim E. Nicols
Kim E. Nicols
Key Points: Ruxolitinib treatment lessens immunopathology and prolongs survival in murine models of hemophagocytic lymphohistiocytosis. In vivo exposure to ruxolitinib limits CD8+ T-cell expansion and proinflammatory cytokine production.

1 May 2018 in Cancer Cell
Verified
Journal Article
Closed access
MCMichelle L. Churchman
Michelle L. Churchman
MQMaoxiang Qian
Maoxiang Qian
GKGeertruy Te Kronnie
Geertruy Te Kronnie
RZRanran Zhang
Ranran Zhang
WYWenjian Yang
Wenjian Yang
CMCharles G Mullighan
Charles G Mullighan

11 July 2019 in Blood
Verified
Journal Article
Open access
PDF file
SASabrin Albeituni
Sabrin Albeituni
KVKatherine C. Verbist
Katherine C. Verbist
PTPaige E. Tedrick
Paige E. Tedrick
HTHeather Tillman
Heather Tillman
JPJennifer Picarsic
Jennifer Picarsic
KNKim E. Nicols
Kim E. Nicols
Hemophagocytic lymphohistiocytosis (HLH) is an often-fatal disorder characterized by the overactivation of T cells and macrophages that excessively produce proinflammatory cytokines, including interferon-γ (IFN-γ). Previously, we reported that the JAK inhibitor ruxolitinib dampens T-cell activation and lessens inflammation in a model of HLH in which perforin-deficient (Prf1−/−) mice are infected with lymphocytic choriomeningitis virus (LCMV). Ruxolitinib inhibits signaling downstream of IFN-γ, as well as several other JAK-dependent cytokines. As a consequence, it remained unclear whether ruxolitinib was exerting its beneficial effects in HLH by inhibiting IFN-γ signaling or by targeting signaling initiated by other proinflammatory cytokines. To address this question, we compared the effects of ruxolitinib with those obtained using an IFN-γ–neutralizing antibody (αIFN-γ) in 2 murine HLH models. In both models, ruxolitinib and αIFN-γ reduced inflammation-associated anemia, indicating that ruxolitinib operates in an IFN-γ–dependent manner to reverse this HLH manifestation. In contrast, the number and activation status of T cells and neutrophils, as well as their infiltration into tissues, were significantly reduced following treatment with ruxolitinib, but they remained unchanged or were increased following treatment with αIFN-γ. Notably, despite discontinuation of ruxolitinib, LCMV-infected Prf1−/− mice exhibited enhanced survival compared with mice in which αIFN-γ was discontinued. This protective effect could be mimicked by transient treatment with αIFN-γ and a neutrophil-depleting antibody. Thus, ruxolitinib operates through IFN-γ–dependent and -independent mechanisms to dampen HLH by targeting the deleterious effects of T cells and neutrophils, with the latter representing an unappreciated and understudied cell type that contributes to HLH pathogenesis.